IO Biotech
IOBT
IOBT was delisted on the 6th of April, 2026.
17 hedge funds and large institutions have $32.8M invested in IO Biotech in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
3.66% less ownership
Funds ownership: 53.21% → 49.55% (-3.7%)
19% less funds holding
Funds holding: 21 → 17 (-4)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
21% less capital invested
Capital invested by funds: $41.6M → $32.8M (-$8.71M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$4.88M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$96.1K |
| 3 |
Morgan Stanley
New York
|
+$18.5K |
| 4 |
Renaissance Technologies
New York
|
+$15.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$4.37M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.93M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$781K |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$433K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$119K |
IOBT Hedge Fund Activity: Q4 2022 in Review
17 of the 6,225 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q4 2022, worth a combined $32.8M — down 21% from $41.6M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IOBT and 0 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Bank of America, adding an estimated $4.88M. The largest seller was PFM Health Sciences, cutting an estimated $4.37M.
- 17 institutional investors held IO Biotech (IOBT) as of Q4 2022, down from 21 in Q3 2022.
- Funds reported $32.8M of IO Biotech stock for Q4 2022, down 21% quarter-over-quarter.
- 0 funds opened new IO Biotech positions in Q4 2022 and 4 closed out, a net change of -4 holders.
- The largest IO Biotech buyer in Q4 2022 was Bank of America, an estimated $4.88M added.
- The largest IO Biotech seller in Q4 2022 was PFM Health Sciences, an estimated $4.37M sold.
Based on aggregated 13F filings for Q4 2022.